What Ethical Issues Arise When Research Involves Patients or People Receiving Care?

What changes when the person inviting research participation is also providing care?

Patients routinely trust clinicians to recommend what is medically appropriate for them. Research operates differently. A study may generate knowledge, compare interventions, randomize treatment, use placebo or control conditions, or follow procedures chosen partly for scientific rather than individualized clinical reasons.

When those two worlds meet, participants can reasonably become confused. A patient may assume that joining a study is part of recommended treatment, that the investigator has selected the study because it is best for them personally, or that refusing might somehow affect the care relationship.

The ethical challenge is not that patients are incapable of deciding. It is that illness and dependence on healthcare can change the context in which the research decision is made.

Patients may need protection from blurred boundaries between research and care

The clinical relationship can change what a research invitation means

Being a patient does not automatically make someone incapable or vulnerable

Patients vary enormously. Someone attending a routine outpatient appointment for a stable condition differs from a critically ill person facing an urgent decision in intensive care. Illness, pain, medication, prognosis, dependency, limited treatment options, and emotional distress can all affect research participation, but not identically.

Researchers should therefore identify the actual source of concern rather than infer vulnerability simply from patient status.

This follows the broader distinction that belonging to a group associated with vulnerability does not determine vulnerability in every study.

Research and clinical care have different purposes

Clinical care is ordinarily organized around the interests and needs of an individual patient. Research is designed to answer a systematic question and produce generalizable knowledge, even when participation may also offer a prospect of direct clinical benefit.

The distinction becomes ethically important when study procedures differ from what clinicians would otherwise choose solely for the patient's individual care.

A clinical trial can certainly provide excellent care. The distinction is about purpose and decision structure, not an assumption that research is inferior care.

Therapeutic misconception can blur that distinction

The term therapeutic misconception is commonly used when research participants fail to appreciate important ways in which research participation differs from individualized clinical care. OHRP's draft guidance on facilitating understanding in informed consent recognizes the concept as an assumption that decisions about a participant's care in research are being made solely with that individual's benefit in mind.

For example, a participant in a randomized trial may assume the physician will simply assign whichever intervention is believed best for them personally. A patient may interpret the word “treatment” as evidence that an experimental intervention is already known to work.

Consent should therefore explain research features that materially differ from ordinary care, such as randomization, placebo or control conditions, protocol-driven procedures, experimental uncertainty, and research-only tests when applicable.

The treating clinician's influence can affect voluntariness

OHRP notes that undue influence can be subtle and gives the example of patients who may feel obligated to participate when their physician is also the investigator.

A physician does not need to threaten a patient for this pressure to exist. Patients are accustomed to taking clinical recommendations seriously. They may also worry about disappointing the clinician or damaging an important therapeutic relationship.

This is a form of dependency-based research vulnerability. Depending on the circumstances, safeguards might include clearer separation of clinical recommendation from research invitation, involvement of another person in consent, additional decision time, or other procedures appropriate to the study.

Refusing research should not mean losing ordinary care

Under the HHS informed-consent requirements, prospective participants must be told that participation is voluntary, refusal involves no penalty or loss of benefits to which they are otherwise entitled, and participants may discontinue participation without penalty or loss of such benefits.

That statement needs to be true in practice.

If the patient believes declining research will jeopardize ordinary treatment, access to clinicians, or services they would otherwise receive, voluntariness becomes questionable. Researchers should therefore distinguish research-specific interventions from ordinary care and explain what treatment alternatives are available when applicable.

Illness can affect capacity temporarily without making every patient incapable

Acute illness, pain, delirium, sedation, hypoxia, medication, severe distress, or other clinical conditions may impair a person's ability to process information or make decisions at a particular time.

OHRP notes that people receiving urgent or emergency medical care may sometimes be vulnerable to coercion or undue influence and that circumstances can affect their ability to process information, ask questions, and evaluate risk.

But illness does not automatically equal incapacity. When capacity is genuinely impaired, researchers should use the appropriate framework for research involving participants with impaired decision-making capacity.

Timing can be an ethical variable

A research invitation made five minutes after receiving a frightening diagnosis may be experienced differently from the same invitation after the patient has had time to understand their clinical situation.

Sometimes urgent research genuinely requires decisions in compressed timeframes. In other cases, the schedule exists because it is convenient for the research workflow.

Researchers should therefore ask whether consent needs to happen now. Additional time can sometimes improve understanding and voluntariness without changing the scientific question.

Research procedures should be distinguished from procedures required for care

Patients may reasonably assume that every blood draw, scan, questionnaire, biopsy, or clinic visit would have occurred anyway. That assumption may affect how they understand research burden and risk.

Where applicable, consent should make clear which procedures are performed because of the research and which are part of ordinary clinical management.

This distinction can also matter for costs, inconvenience, incidental findings, additional radiation or sampling, and what happens after research participation ends.

Privacy can be complicated by access to clinical information

Clinical research may involve health records, laboratory results, imaging, genetic information, diagnoses, medication histories, or other sensitive information generated during care.

Researchers should determine what access is scientifically necessary, how data will be used, who will receive them, and which privacy and confidentiality rules apply. Consent to medical treatment should not be assumed to constitute consent to every research use of clinical information.

Requirements vary by jurisdiction and research context, including whether health-privacy laws, research regulations, waivers, authorizations, or other mechanisms apply.

Research can be valuable to patients without promising personal benefit

Patients may participate for many reasons: possible direct benefit, access to an intervention, altruism, trust in clinicians, interest in science, or a desire to help future patients.

Researchers should distinguish benefits reasonably expected for the individual participant from the societal value of producing knowledge. A study can be scientifically important without offering direct clinical benefit to everyone enrolled.

This distinction becomes particularly important when discussing randomization, placebo, nontherapeutic procedures, or early-phase research.

A patient hears “treatment option” when the physician means “research opportunity”

Clinical familiarity can make research boundaries seem clearer to researchers than they are to patients

Make the boundary between care and research visible

These are examples of how additional safeguards should respond to the source of vulnerability rather than simply to the fact that participants are patients.

Before recruiting patients, check whether care and research are becoming blurred

Frequently asked questions about patients in research

A patient needs to know when the clinician has changed hats

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.